Press Release

Embargoed until: 00:01 GMT, Monday 9 March 2020

New initiative to give cancer patients easier access to clinical trials and increase patient diversity in research

The Christie NHS Foundation Trust and Innovative Trials, a clinical trial patient recruitment company, have today (Monday 9 March) announced a pioneering partnership to tackle the issue of patient diversity within clinical trials and help speed up research so that effective treatments come to market faster.

According to Innovative Trials, a major challenge facing clinical trials is recruiting enough eligible patients to make the research viable. Clinical trials that do not recruit or retain enough participants are at risk of failing. Another challenge is the current lack of diversity among patients who do participate in research. This can make it difficult to assess how effective medical treatments are for different groups of people.

The partnership between The Christie and Innovative Trials aims to tackle both issues by raising awareness of clinical research and increasing clinical trial participation among cancer patients — particularly those from black, Asian and minority ethnic communities — who live in or around Oldham, Wigan, Wythenshawe, Preston, Macclesfield and Stoke-on-Trent.

Penny Morrison, patient recruitment strategy director for Innovative Trials, explained: “Recruiting people into clinical trials has always been challenging for the pharmaceutical industry. Part of the problem is that general awareness of clinical research — why it is important and what it involves — and clinical trial opportunities is low. We also know that people from minority ethnic communities are traditionally under-represented in research. This is why increasing patient diversity within clinical trials is so vital: to ensure medical treatments work for all groups.”

Penny Morrison added: “We are delighted to be working alongside The Christie, one of the UK’s leading cancer centres, to help them tackle this issue. It is an exciting step towards changing the landscape for clinical trial participation, making them easier to access for more diverse population groups and increasing participation overall.”

Innovative Trials will use its expertise to interact with local communities and healthcare professionals to identify and engage with appropriate patients. The company will create bespoke and culturally appropriate materials designed to educate prospective clinical trial participants to ensure they are fully informed, and work with the clinical research delivery teams to make sure they are able to keep patients engaged for the duration of their trial.

As well as benefiting from clinical research much faster, they will be able to access these treatments in local Christie cancer centres rather than travelling to The Christie’s main site in Manchester. By partnering with Trusts and working as a network to increase access to clinical trials across the UK, the Christie is looking to transform approaches to healthcare.

Professor Andrew Wardley, consultant medical oncologist at The Christie and project lead for this initiative, said: “We’re looking forward to working with Innovative Trials to give thousands of cancer patients the opportunity to access new therapies and new combinations of therapies to help them increase their chance of survival.

“It’s important that we’re able to offer our patients the best treatment and care, and a big part of this is access to clinical trials and the new treatments being developed. However, one of the challenges we face is making sure patients and their clinicians know what opportunities are available – fewer than 50 percent of cancer patients recall having clinical trials discussed with them following their diagnosis. We hope this initiative with Innovative Trials will help to reduce such variation between providers so that more patients can benefit from new treatments at the earliest opportunity.”

This initiative to increase opportunities for patients to participate in and benefit from clinical research supports NHS England’s Five Year Forward View of accelerating health innovation and new ways of delivering care. The Christie’s overall outreach project to provide more localised care is in collaboration with the National Institute of Health Research (NIHR), Clinical Research Network (CRN) Greater Manchester.

-Ends-

For more information or to arrange any interviews, please contact Laura Gibson at Presence Media on +44 7771 933609 or laura@presence-media.co.uk

Notes to editors

  • 80% of clinical trial sponsors say finding eligible patients is a significant barrier to recruitment
  • 80% of trials miss their recruitment target dates
  • Delays in patient recruitment can cost up to £27,000 per day

About Innovative Trials

Innovative Trials ensures that clinical trials recruit informed patients within a timely manner. This enables potential new treatments to come to market as early as possible to provide alternative therapeutic options for present and future patients.
Founded in 2010, the company works alongside pharmaceutical and clinical research organisations to ensure that patients enrolling onto clinical trials are fully informed of what the research will involve for themselves and their families.
Based near Welwyn Garden City in Hertfordshire, Innovative Trials employs around 33 members of staff in the UK. The company works internationally with a further 60 people stationed overseas in 58 countries to help clinical trial researchers recruit eligible patients and keep them involved.
For more information, visit www.innovativetrials.co.uk

Need support to recruit patients to your clinical trial?
Contact us to find out how we can help you.

Contact

Therapy Areas

We have extensive experience of study phases Ib to IV, adults and paediatrics and both acute and chronic conditions.

Contact
  • Intra abdominal pain
  • Post operative pain
  • Non Alcoholic Fatty Liver Disease (NAFLD)
  • Non Alcoholic steatohepatitis (NASH)
  • Hypercholesterolaemia
  • Type II Diabetes
  • Anaemia
  • Haemophilia
  • Sickle Cell
  • Thrombocytopenia
  • Osteoarthritis
  • Atopic Dermatitis
  • Hidradenitis Suppurativa
  • Psoriasis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Bacterial infection – Sepsis
  • C-Diff
  • Intra-abdominal infectious disease
  • Pneumonia
  • Ankylosing Spondylitis
  • Alopecia
  • Asthma
  • Atopic Dermatitis
  • Crohn’s Disease
  • Hidradenitis Suppurativa
  • Lupus
  • Nasal Polyps
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis
  • Vitiligo
  • Alzheimer’s Disease
  • Epilepsy
  • Depression
  • Duchenne Muscular Dystrophy (DMD)
  • Dyskinesia in Cerebral Palsy
  • Migraine
  • Multiple Sclerosis
  • Parkinson’s Disease
  • Schizophrenia
  • Acute Myeloid Leukaemia
  • Basal cell carcinoma
  • Bladder Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Head & Neck Cancer
  • Liver cancer
  • Lung Cancer
  • Lymphoma
  • Metastatic bone pain
  • Myelofibrosis
  • Mutant Tumours
  • NSCLC
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Solid Tumour
  • Treatment Resistance post cancer treatment
  • Urothelial Cancer
  • Asthma
  • COPD
  • Over-active bladder
  • Pneumonia
  • Urinary Tract Infection
  • Birth control
  • Interstitial cystitis
  • STD Prevention
  • Urinary Tract Infection